Veru’s obesity drug roughly as safe as Wegovy; Keros’ board fight
Plus, news about Advanz, Alvotech and GeNeuro: Veru’s obesity drug generally safe when added to Wegovy: In the Phase 2b QUALITY trial, patients who were given enobosarm, an oral androgen receptor modulator …
GLP-1 prescriptions for weight loss soar, despite obstacles
The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, according to a new report.
Cysteine Deficiency Drives Weight Loss by Depleting CoA
This research paper explores the impact of amino acid restriction on weight loss, focusing on the unique effects of cysteine deficiency. The study demonstrates that cysteine restriction in mice, particularly those with compromised cysteine synthesis, leads to rapid and significant weight loss, primarily through fat reduction. This weight loss is linked to the activation of stress responses, reduced levels of key metabolites like CoA, and resulting metabolic inefficiency, […]
Blue Cross Blue Shield plans reverse course on GLP-1 coverage
Blue Cross plans are retreating from GLP-1 weight-loss drug coverage after spending hundreds of millions of dollars on the highly popular medications.
Author Correction: GLP-1-based therapies for diabetes, obesity and beyond
Nature Reviews Drug Discovery, Published online: 28 May 2025; doi:10.1038/s41573-025-01231-3 Author Correction: GLP-1-based therapies for diabetes, obesity and beyond
Weight-loss drugs may lower risk of obesity-related cancers
Popular GLP-1 weight-loss drugs like Ozempic and Zepbound can help reduce a woman’s risk for as many as 14 cancers associated with obesity, a new study says.
Weight-Loss Drugs May Lower Risk Of Obesity-Related Cancers
By Dennis Thompson HealthDay ReporterWEDNESDAY, May 28, 2025 (HealthDay News) — Popular GLP-1 weight loss drugs like Ozempic and Zepbound can help…
Novo Nordisk’s 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?
Nothing attracts competition like the opportunity for profits, and the weight loss drug market has become arguably the healthcare industry’s hottest opportunity in recent memory. Novo Nordisk (NYSE: NVO) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy. However, competition is picking up with multiple next-generation drugs working through clinical testing. […]
Can GLP-1s Protect Against Obesity-Related Cancers?
GLP-1 receptor agonists may modestly reduce the risk for 14 obesity-related cancers, especially colorectal cancer, among adults with obesity and diabetes, new data suggest. Medscape Medical News
Patenting Privation (Part III): Empowering Revenge
Just over a year ago on these pages, I continued our look at the patent franchises protecting the defining drugs of our time, Novo Nordisk and Eli Lilly’s diabetes/weight-loss blockbusters, Ozembic/Wegovy and Mounjaro/Zepbound. As you can imagine with drugs of such culture-defining magnitude, the year that has passed since that column has been full of […]